Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 26, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 600,000 ordinary shares of 25 pence each.
- Purchase Price: 1,459.235 pence per share.
- Treasury Holdings: 202,591,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,784,959,036 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2006. The company executed the purchase on October 26, 2006, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 600,000 share repurchase based on the disclosed price of 1,459.235 pence.
- Confirm the updated total share count (5,784,959,036 in issue) against subsequent filings.
- Review the May 17, 2006 Annual General Meeting minutes to understand the full scope of the share buyback authorization.
- Note that this filing does not contain operational or financial performance data for the period.